Sweden's Isofol Medical Q4 loss narrows

Isofol Medical AB (publ)

18/02/2026 06:39

Overview

Swedish cancer therapeutics firm reported no Q4 revenue, consistent with prior year

Q4 net loss narrowed slightly compared to previous year

Company secured new patent for arfolitixorin, extending protection until 2043

Outlook

Company did not provide specific financial guidance for the current quarter or full year

Result Drivers

CLINICAL STUDY PROGRESS - CEO noted significant interest in arfolitixorin as clinical study progresses

PATENT DEVELOPMENT - EPO issued Intention to Grant for new patent for arfolitixorin, securing protection until 2043

SCIENTIFIC CONGRESS PARTICIPATION - Co presented study design at ESMO and ASCO-GI cancer congresses

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Meet
SEK 0
SEK 0 (1 Analyst)
Q4 EPS
-SEK 0.05
Q4 Net Income
-SEK 12.78 mln


Analyst Coverage

Wall Street's median 12-month price target for Isofol Medical AB (publ) is SEK1.70, about 179.8% above its February 17 closing price of SEK0.61

Press Release: ID:nMFN2Xch4Y

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)